Filing would offer added protection to IP already submitted to USPTO VANCOUVER, BC, June 22, 2022 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has…

Source

Previous articleBright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
Next articleSmall Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022